Prof. Wenhao Ouyang - Tumor Immunology - Best Researcher Award

Sun Yat-Sen Memorial Hospital - China

AUTHOR PROFILE

EARLY ACADEMIC PURSUITS:

Wenhao Ouyang commenced his academic journey at Sun Yat-sen University, delving into the field of Medical Oncology. His early academic pursuits laid the foundation for a career marked by dedication to advancing cancer research and treatment.

PROFESSIONAL ENDEAVORS:

As a Physician and Ph.D. Candidate at Sun Yat-sen Memorial Hospital, Wenhao Ouyang's professional endeavors center around tumor big data, artificial intelligence research, tumor immunology, and immunotherapy research. His dual role as both a clinician and researcher highlights his commitment to bridging the gap between clinical practice and cutting-edge research.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Wenhao Ouyang has made substantial contributions to the field through his research, focusing on tumor big data, artificial intelligence, and tumor immunology. His published articles in esteemed journals showcase the depth and breadth of his research, with a focus on prognostic factors, immunotherapy response, and the tumor microenvironment.

IMPACT AND INFLUENCE:

Ouyang's impact is evident through his published articles, each addressing critical aspects of cancer research. His work, such as developing prognostic risk scores and identifying immune-inflammation signatures, reflects his influence on shaping the understanding of cancer prognosis and treatment response.

ACADEMIC CITES:

Being a reviewer for Frontiers in Immunology underscores Wenhao Ouyang's standing in the academic community. Reviewing articles in this reputable journal demonstrates his expertise and recognition within the field, contributing to the advancement of scientific knowledge.

LEGACY AND FUTURE CONTRIBUTIONS:

Wenhao Ouyang's legacy is unfolding through a substantial body of work that has already left a mark on cancer research. His role as a major participant in the selection of articles for the 2023 ESMO Asia poster highlights his commitment to sharing knowledge and advancing the field on a global scale.

HIGHLIGHT OF FUTURE CONTRIBUTIONS:

Looking forward, Ouyang's involvement in groundbreaking projects, such as multimodal data fusion for improved risk stratification of breast cancer, signals a trajectory of continued impact. His role in precision neoadjuvant chemotherapy and distinguishing tumor immunotyping heterogeneity positions him as a key figure in shaping the future of cancer research and treatment.

NOTABLE PUBLICATION

Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy. 2023 (1)

Machine learning radiomics of magnetic resonance imaging predicts recurrence-free survival after surgery and correlation of LncRNAs in patients with breast cancer: a multicenter cohort study. 2023 (1)

Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer. 2023

A Comprehensive Analysis of Programmed Cell Death-Associated Genes for Tumor Microenvironment Evaluation Promotes Precise Immunotherapy in Patients with Lung Adenocarcinoma. 2023

Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma. 2022 (2)

A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma. 2022 (19)

EARLY ACADEMIC PURSUITS:

Mario I. Vega initiated his academic journey at the Universidad Autónoma Metropolitana Campus Xochimilco, Mexico City, serving as a Research Technical Assistant in the Department of Leptospirosis Human Research from 1991 to 1992. He continued his research roles at the Hospital Infantil de Mexico "Federico Gomez" and the Instituto Mexicano del Seguro Social (IMSS) with a focus on immunology and infectious diseases.

PROFESSIONAL ENDEAVORS:

Mario I. Vega's professional trajectory includes positions at prestigious institutions, such as UCLA AIDS Institute and IMSS, where he advanced from Assistant Researcher to Professor in the field of tumor immunology and infectious diseases. Notably, he has been associated with UCLA Medical Center, Jonsson Comprehensive Cancer Center, contributing as Staff Associate Researcher in the Clinical Nutrition Division.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY:

Dr. Vega's research contributions span diverse areas, from rituximab inhibition of p38 MAPK activity in B NHL to extensive work in immunology, cancer, and infectious diseases. His research expertise includes molecular biology, DNA replication, PCR, and immunotherapy. Serving on various review committees and editorial boards, he has actively contributed to scientific evaluations and publications.

IMPACT AND INFLUENCE:

Dr. Mario I. Vega's impact is evident through numerous honors and awards, such as the American Society of Hematology (ASH) Travel Award in 2004 and consecutive Fogarty fellowships at UCLA from 2004 to 2013. His recognition extends to national and international awards in pediatric research, biomedical research, and contributions to scientific journals.